Biomarkers 2014 Keynote Speakers

Andreas Jeromin President & Cso, Atlantic Biomarkers LLC Andreas Jeromin, PhD, has established research programs in translational neuroscience in both industry and biotech for the last 15 years and co-authored more than 100 publications. He has also been elected a member of the Dana Alliance for Brain Initiatives. Andreas Jeromin has led biomarker qualification programs in diagnostics and therapeutics in acute neurological injury and neurodegeneration in roles with increased responsibilities. This included several drug development program from POC to a NINDS-supported phase III trial (Protect III). He also supports as member of the SABs or steering committee, several biomarker qualification efforts such as ADNI, the Coalition against Major Diseases (CAMD) directed by the Critical Path Institute (C-PATH), the Alzheimer's Association CSF QC and biomarker assay standardization initiatives in other CNS disorders, including MS (Accelerated Cure), ALS and PD. He is the founder and CSO of Atlantic Biomarkers, LLC, and joined Quanterix, Inc. as scientific and medical advisor in 2014.
Declan Jones Neuroscience Therapeutic Area Lead, J&J London Innovation Centre Declan N.C. Jones, PhD joined the newly established J&J London Innovation Centre in June 2013 as VP and Neuroscience Lead. The London Innovation Centre (http://www.jnjinnovation.com/) will build relationships with the academic institutions, biotech organizations and venture capital firms in the UK and will be a base for outreach throughout Europe. Declan is particular focused on identifying opportunities for the treatment for Alzheimer’s disease and mood disorders, including diagnostics and biomarkers. Prior to this role, Declan was Head of Research for GlaxoSmithKline’s Centre of Excellence for External Drug Discovery (CEEDD) after spending fourteen years in roles with increasing responsibility in CNS drug discovery within GlaxoSmithKline, finishing as Director of In Vivo Neurobiology and also Disease Area Strategy Leader for Schizophrenia and Bipolar Disorders.
Thomas Joos Deputy Managing Director, University of Tuebingen Dr. Joos joined 1998 the NMI at the University of Tuebingen heading the department of biochemistry. Since 2013 he is the deputy managing director. His research is focused on miniaturized multiplexed immunoassays for biomarker research and diagnostic applications. Dr. Joos studied Biochemistry at the University of Tübingen. He performed his Ph.D. degree in 1985 on integrin-?5 during early embroygenesis of Xenopus laevis in the laboratory of Prof. Peter Hausen at the Max-Planck-Institute of Developmental Biology. Dr. Joos is a member of the editorial board of Drug Discovery Today, Proteomics, Molecular Biotechnology and Expert Review of Proteomics. He is a member of the scientific advisory board of the "Plasma Proteome Institute" Washington, DC, USA, of the “AlbaNova VINN Excellence Centre for Protein Technology (ProNova)” at the Royal Institute of Technology, Stockholm, Sweden, and of Myriad-RBM, Austin, TX, USA.
Alain Van Gool Head of Biomarkers in Personalised Healthcare, TNO Alain van Gool specializes in translational biomarkers in pharmaceutical drug development, with particular interest in applications in personalized healthcare. His professional background is a mix of academia (1991-1998; ErasmusMC, Cancer UK; 2009-now, Radboud University Nijmegen), pharmaceutical industry (1999-2011; Organon, Schering-Plough, MSD), applied research institute (2011-now; TNO), and university medical center (2011-now; Radboudumc). He has lead technology-based laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of disease areas. While working in Europe, USA and Asia, he and his teams contributed to over 150 projects in various phases of biomarker R&D. His technical expertise resides most strongly in molecular profiling technologies (genetics, genomics, proteomics, metabolomics, bioinformatics) and their applications in scientific research. His current positions are Head of biomarkers in personalized healthcare at TNO, Head of the Radboud center for proteomics, glycomics and metabolomics, and Coordinator of Radboudumc Technology Centers of the Radboud University Medical Center, and professor Molecular Profiling at the Radboud University Nijmegen (Netherlands). He serves on scientific advisory boards of several organisations and has been a frequently invited thought leader and speaker at translational medicine events.